Eli Lilly & Co. (LLY) Unit to Acquire Rabies Vaccine Portfolio from Boehringer Ingelheim

October 5, 2016 7:07 AM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Boehringer Ingelheim Vetmedica Inc. (BIVI) announced an agreement with Elanco U.S., Inc., a subsidiary of Eli Lilly and Company (NYSE: LLY), to sell a portfolio of U.S. canine, feline and rabies vaccines, as well as a fully integrated manufacturing and R&D site, to Elanco. The sale price of $885 million includes the estimated cost of acquired inventory. The deal is conditioned on antitrust approval and closing of the Boehringer Ingelheim (BI) asset swap transaction with Sanofi that was signed in June 2016.

"This agreement is an important step toward a successful acquisition of Merial," said Dr. Albrecht Kissel, president and CEO of Boehringer Ingelheim Vetmedica Inc. "This was a highly complex decision from a business and from an emotional perspective. It was certainly not taken lightly particularly in view of the history and significant positive developments of this business over the past years."

"We are confident that, under Elanco's leadership, customers will continue to have access to these innovative vaccines and the portfolio will have strong support," Kissel added.

The current BIVI vaccine portfolio has experienced consistent revenue growth over the past three years. Just this year, the company launched two new vaccines, ULTRA Hybrid FVRCP and ULTRA™ Duramune® Lyme, both available in the innovative 0.5mL dose developed by BIVI.

The sale to Elanco is anticipated to close by early 2017 subject to approval by the Federal Trade Commission, and other contingencies.

Products included within the proposed Elanco acquisition:

Canine: Duramune®

  • Duramune® Max 5/4L
  • Duramune® Max 5
  • Duramune® Max 5-Cvk/4L
  • Duramune® Max 5-Cvk
  • Duramune® Max Pv
  • Duramune® CV-K
  • Duramune® Max PC
  • Duramune® Adult 3
  • LeptoVax® 4
  • LeptoVax® 4/C


  • Bronchi-Shield® ORAL
  • Bronchi-Shield® III

Duramune Lyme®

  • Duramune Lyme®
  • Duramune Lyme® +LeptoVax® 4
  • Duramune Lyme® +Leptovax® 4/C
  • Duramune Lyme® +Max 5/4L
  • Duramune Lyme® +Max5-CvK/4L
  • Duramune Lyme® +Max5-CvK

ULTRA Duramune®

  • ULTRA Duramune® DAP+4L
  • ULTRA Duramune® DAP
  • ULTRA Duramune® 4L
  • ULTRA Duramune® DAP+C4L
  • ULTRA Duramune® DAP+C
  • ULTRA Duramune® Lyme

Feline: Fel-O-Vax®

  • Fel-O-Vax Lv-K® III + CaliciVax®
  • Fel-O-Vax® Lv-K®
  • Fel-O-Vax® Lv-K/FIV
  • Fel-O-Vax® IV+CaliciVax®
  • Fel-O-Vax® PCT+CaliciVax®
  • Fel-O-Vax® Lv-K IV+CaliciVax®
  • Fel-O-Vax® FIV
  • CaliciVax®

ULTRA Fel-O-Vax®

  • ULTRA Fel-O-Vax® FVRCP
  • ULTRA Fel-O-Vax® FeLV
  • ULTRA Fel-O-Vax® Dual FCV
  • ULTRA Hybrid FVRCP


  • Fel-O-Guard® Plus 3
  • Fel-O-Guard® Plus 3+Lv-K
  • Fel-O-Guard® Plus 4
  • Fel-O-Guard® Plus 4 +Lv-K

Rabies Rabvac®

  • Rabvac® 3
  • Rabvac® 1

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Management Comments, Mergers and Acquisitions

Related Entities

Definitive Agreement

Add Your Comment